Behavioral change in a cancer patient following intrathecal beta-endorphin administration.
A patient with a disseminated malignancy received 3 mg of synthetic beta-endorphin administered intrathecally by lumbar puncture. A marked behavioral syndrome characterized by confusion, hypomanic/manic behavior, and psychosis followed drug administration and persisted for more than 2 days.
D001714:Bipolar Disorder / Q000139:chemically induced; D003221:Confusion / Q000139:chemically induced; D004723:Endorphins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010166:Palliative Care; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D001615:beta-Endorphin
D004723:Endorphins; D001615:beta-Endorphin